Eli Lilly acquires Morphic Holding for $3.2B, focusing on IBD treatment opportunities
07/08/24, 3:59 PM
Location
indianapoliswalthamIndustry
pharmaceutical
manufacturing
health care
biopharma
therapeutics
biotechnology
Eli Lilly has purchased Morphic Holding for $3.2 billion, intending to leverage its expertise in the field of gastroenterology. The acquisition is in line with Lilly's commitment to developing new therapies for the benefit of patients, especially in the treatment of inflammatory bowel disease (IBD).
Company Info
Location
Indianapolis, Indiana, United States
Company info
Lilly is a medicine company turning science into healing to make life better for people around the world. They have been pioneering life-changing discoveries for nearly 150 years, and today their medicines help more than 51 million people across the globe. Lilly is focused on redefining diabetes care, treating obesity, advancing the fight against Alzheimer's disease, providing solutions to immune system disorders, and transforming difficult-to-treat cancers into manageable diseases.